Cell Therapy Maker Pluri Takes 50% of ZEO to Crack Regenerative Medicine's $400K Cost Floor
· techtimes.com · popularity 21/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at techtimes.com →
Summary
Regenerative medicine commercialization advanced October 26, 2026, as Pluri Inc. and ZEO ScientifiX announced a 50-50 equity partnership pairing Pluri's industrial 3D cell expansion platform with ZEO's 600-physician U.S. network. ZEO gains exclusive Cellav aesthetics distribution rights while Pluri targets cell therapy's $400K per-treatment cost barrier.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 1.